{"classes":[{"categories":[{"measurements":[{"comment":"Predose of Cycle 1 Day 1 administration of Paclitaxel.","groupId":"OG000","spread":"NA","value":"NA"},{"comment":"Predose of Cycle 1 Day 1 administration of Paclitaxel.","groupId":"OG001","spread":"NA","value":"NA"},{"comment":"Predose of Cycle 1 Day 1 administration of Paclitaxel.","groupId":"OG002","spread":"NA","value":"NA"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"28"},{"groupId":"OG001","value":"35"},{"groupId":"OG002","value":"24"}],"units":"Participants"}],"title":"Cy1D1 Pre-dose"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"2800","value":"4850"},{"groupId":"OG001","spread":"3640","value":"6440"},{"groupId":"OG002","spread":"2590","value":"5560"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"26"},{"groupId":"OG001","value":"34"},{"groupId":"OG002","value":"24"}],"units":"Participants"}],"title":"Cy1D1 Before End of Infusion"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"2790","value":"2300"},{"groupId":"OG001","spread":"3020","value":"2490"},{"groupId":"OG002","spread":"1780","value":"1980"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"27"},{"groupId":"OG001","value":"32"},{"groupId":"OG002","value":"23"}],"units":"Participants"}],"title":"Cy1D1 After Infusion"},{"categories":[{"measurements":[{"comment":"Mean or SD is not reported because more than half of the samples at the specified timepoint are below the limit of quantification.","groupId":"OG000","spread":"NA","value":"NA"},{"comment":"Mean or SD is not reported because more than half of the samples at the specified timepoint are below the limit of quantification.","groupId":"OG001","spread":"NA","value":"NA"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"0"}],"units":"Participants"}],"title":"Cy2D21"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"3610","value":"5810"},{"groupId":"OG001","spread":"4510","value":"7810"},{"groupId":"OG002","spread":"5160","value":"7810"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"19"},{"groupId":"OG001","value":"25"},{"groupId":"OG002","value":"16"}],"units":"Participants"}],"title":"Cy3D1 Before End Of Infusion"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"1660","value":"1800"},{"groupId":"OG001","spread":"5830","value":"2990"},{"groupId":"OG002","spread":"1380","value":"1930"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"19"},{"groupId":"OG001","value":"27"},{"groupId":"OG002","value":"17"}],"units":"Participants"}],"title":"Cy3D1 After Infusion"}],"denoms":[{"counts":[{"groupId":"OG000","value":"28"},{"groupId":"OG001","value":"35"},{"groupId":"OG002","value":"24"}],"units":"Participants"}],"dispersionType":"Standard Deviation","groups":[{"description":"Participants received intravenous (IV) infusion of atezolizumab on Day 1 of each 21-day cycle followed by IV infusion of paclitaxel and carboplatin on Day 1 of each 21-day cycle for 4 or 6 cycles or until loss of clinical benefit whichever occurs first, during induction treatment phase. Participants received IV infusion of atezolizumab during maintenance treatment phase until loss of clinical benefit.","id":"OG000","title":"Arm A (Atezolizumab+Paclitaxel+Carboplatin)"},{"description":"Participants received IV infusion of atezolizumab and bevacizumab on Day 1 of each 21-day cycle followed by IV infusion of paclitaxel and carboplatin on Day 1 of each 21-day cycle for 4 or 6 cycles or until loss of clinical benefit whichever occurs first, during induction treatment phase. Participants received IV infusion of atezolizumab until loss of clinical benefit and bevacizumab until progressive disease, unacceptable toxicity, or death during maintenance treatment phase.","id":"OG001","title":"Arm B (Atezolizumab+Bevacizumab+Paclitaxel + Carboplatin)"},{"description":"Participants received IV infusion of bevacizumab on Day 1 of each 21-day cycle followed by IV infusion of paclitaxel and carboplatin on Day 1 of each 21-day cycle for 4 or 6 cycles or loss of clinical benefit whichever occurs first, during induction treatment phase. Participants received IV infusion of bevacizumab during maintenance treatment phase until progressive disease, unacceptable toxicity, or death.","id":"OG002","title":"Arm C (Bevacizumab+Paclitaxel+Carboplatin)"}],"paramType":"MEAN","populationDescription":"The pharmacokinetic-evaluable population is defined as all patients who received any dose of atezolizumab, bevacizumab, carboplatin, or paclitaxel and who had evaluable PK samples post-dose.","reportingStatus":"POSTED","timeFrame":"Predose (same day of treatment administration), 5-10 minutes before end of paclitaxel infusion, 1 h after paclitaxel infusion (infusion duration=3 h) on D1 of Cy1,3 (Cycle length=21 days)","title":"Plasma Concentrations for Paclitaxel in Arm A, Arm B, and Arm C","type":"SECONDARY","unitOfMeasure":"ng/mL"}